This study is a multicenter study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of treatment with SNH-119014 in adult participants with non-transfusion-dependent thalassemia. 30 participants with non-transfusion-dependent thalassemia were enrolled.
Male or Female;
Documented diagnosis of thalassemia;
Non-transfusion-dependent;
Hb concentration ≤10.0 grams per deciliter (g/dL) during the screening period;
Hemoglobin S forms of thalassemia;
History of Congestive Heart Failure Within 6 months prior to signed informed consent;
Myocardial Infarction/unstable angina Within 6 months prior to signed informed consent;
Deep Vein Thrombosis/stroke/thromboembolic events Within 6 months prior to signed informed consent;
ScinnoHub Pharmaceutical Co., Ltd.
Lead sponsor